Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition in which an organic thrombus remains in the pulmonary artery (PA) even after receiving anticoagulation therapy for more than 3 months and is complicated by pulmonary hypertension (PH), leading to right-sided heart failure and death...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/4/3979 |
| _version_ | 1797620414546968576 |
|---|---|
| author | Naoyuki Otani Ryo Watanabe Takashi Tomoe Shigeru Toyoda Takanori Yasu Takaaki Nakamoto |
| author_facet | Naoyuki Otani Ryo Watanabe Takashi Tomoe Shigeru Toyoda Takanori Yasu Takaaki Nakamoto |
| author_sort | Naoyuki Otani |
| collection | DOAJ |
| description | Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition in which an organic thrombus remains in the pulmonary artery (PA) even after receiving anticoagulation therapy for more than 3 months and is complicated by pulmonary hypertension (PH), leading to right-sided heart failure and death. CTEPH is a progressive pulmonary vascular disease with a poor prognosis if left untreated. The standard treatment for CTEPH is pulmonary endarterectomy (PEA), which is usually performed only in specialized centers. In recent years, balloon pulmonary angioplasty (BPA) and drug therapy for CTEPH have also shown good results. This review discusses the complex pathogenesis of CTEPH and presents the standard of care, PEA, as well as a new device called BPA, which is showing remarkable progress in efficacy and safety. Additionally, several drugs are now demonstrating established evidence of efficacy in treating CTEPH. |
| first_indexed | 2024-03-11T08:42:06Z |
| format | Article |
| id | doaj.art-9a2a4f703ebf430a90e02ab3ca75da18 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T08:42:06Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9a2a4f703ebf430a90e02ab3ca75da182023-11-16T21:07:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01244397910.3390/ijms24043979Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary HypertensionNaoyuki Otani0Ryo Watanabe1Takashi Tomoe2Shigeru Toyoda3Takanori Yasu4Takaaki Nakamoto5Department of Cardiology, Dokkyo Medical University Nikkyo Medical Center, Nikko 321-1298, JapanDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu 321-0293, JapanDepartment of Cardiology, Dokkyo Medical University Nikkyo Medical Center, Nikko 321-1298, JapanDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu 321-0293, JapanDepartment of Cardiology, Dokkyo Medical University Nikkyo Medical Center, Nikko 321-1298, JapanDepartment of Cardiology, Dokkyo Medical University Nikkyo Medical Center, Nikko 321-1298, JapanChronic thromboembolic pulmonary hypertension (CTEPH) is a condition in which an organic thrombus remains in the pulmonary artery (PA) even after receiving anticoagulation therapy for more than 3 months and is complicated by pulmonary hypertension (PH), leading to right-sided heart failure and death. CTEPH is a progressive pulmonary vascular disease with a poor prognosis if left untreated. The standard treatment for CTEPH is pulmonary endarterectomy (PEA), which is usually performed only in specialized centers. In recent years, balloon pulmonary angioplasty (BPA) and drug therapy for CTEPH have also shown good results. This review discusses the complex pathogenesis of CTEPH and presents the standard of care, PEA, as well as a new device called BPA, which is showing remarkable progress in efficacy and safety. Additionally, several drugs are now demonstrating established evidence of efficacy in treating CTEPH.https://www.mdpi.com/1422-0067/24/4/3979balloon pulmonary angioplastypulmonary endarterectomychronic thromboembolic pulmonary hypertension |
| spellingShingle | Naoyuki Otani Ryo Watanabe Takashi Tomoe Shigeru Toyoda Takanori Yasu Takaaki Nakamoto Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension International Journal of Molecular Sciences balloon pulmonary angioplasty pulmonary endarterectomy chronic thromboembolic pulmonary hypertension |
| title | Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension |
| title_full | Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension |
| title_fullStr | Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension |
| title_full_unstemmed | Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension |
| title_short | Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension |
| title_sort | pathophysiology and treatment of chronic thromboembolic pulmonary hypertension |
| topic | balloon pulmonary angioplasty pulmonary endarterectomy chronic thromboembolic pulmonary hypertension |
| url | https://www.mdpi.com/1422-0067/24/4/3979 |
| work_keys_str_mv | AT naoyukiotani pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension AT ryowatanabe pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension AT takashitomoe pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension AT shigerutoyoda pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension AT takanoriyasu pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension AT takaakinakamoto pathophysiologyandtreatmentofchronicthromboembolicpulmonaryhypertension |